Company Pharmosa Biopharm Inc.

Equities

6875

TW0006875008

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Company contact information

Sector

Sales per region

Sector Other Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 23:00:00 26/06/2024 BST			5-day change	1st Jan Change
74 ^TWD	+5.71%		+3.93%	-15.91%

05-15	Pharmosa Biopharm Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-28	Pharmosa Biopharm Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Pharmosa Biopharm Inc is a Taiwan-based company mainly engaged in the research and development of new drugs. The main products include L606, for the treatment of Category I pulmonary arterial hypertension (PAH); L606, for the treatment of Category III pulmonary hypertension caused by interstitial lung disease (PH-ILD); L606, for the treatment of chronic thromboembolic Category IV pulmonary hypertension (CTEPH); L608, for the treatment of Category I pulmonary arterial hypertension (PAH).

TWD in Million	2022	Weight	2023	Weight	Delta
New Drug Development 100.0 %	0	nan %	315	100.0 %	-

TWD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	-	-	315	100.0 %	-

Managers	Title	Age	Since
Pei Kan CEO	Chief Executive Officer	-	31/03/18
Shu Ping Yang DFI	Director of Finance/CFO	-	31/05/15
Ko Chieh Chen CTO	Chief Tech/Sci/R&D Officer	-	-
Hui An Pao COO	Chief Operating Officer	-	18/09/16
Ju Yi Lin ADM	Chief Administrative Officer	58	31/05/15

Members of the board	Title	Age	Since
Li Jen Wu BRD	Director/Board Member	-	09/01/22
Ko Jui Shih BRD	Director/Board Member	-	24/10/21
Wen Chang Chang BRD	Director/Board Member	-	09/01/22
Chien Chih Wang CHM	Chairman	-	20/06/16
Yan Ling Fang BRD	Director/Board Member	66	09/01/22
Pei Kan CEO	Chief Executive Officer	-	31/03/18
Wen Hsu Yan BRD	Director/Board Member	-	-
Chi Heng Chien BRD	Director/Board Member	-	-
Te Chun Kung BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	129,018,004	79,397,004 ( 61.54 %)	0	61.54 %

Pharmosa Biopharm, Inc.

3/F-3, 66 Sanchong Road Nangang District

115602, Taipei

http://www.pharmosa.com.tw

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARMOSA BIOPHARM INC.	-15.91%	293M
LONZA GROUP AG	+38.85%	39.1B
IQVIA HOLDINGS INC.	-7.64%	38.76B
ALNYLAM PHARMACEUTICALS, INC.	+27.22%	31.24B
ICON PUBLIC LIMITED COMPANY	+11.60%	25.9B
CELLTRION, INC.	-13.75%	25.8B
UNITED THERAPEUTICS CORPORATION	+45.30%	14.06B
MEDPACE HOLDINGS, INC.	+40.73%	13.12B
BIO-TECHNE CORPORATION	-6.28%	11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.37%	10.68B

Other Biotechnology & Medical Research